Across TCGA pan-cancer cohorts, S100A16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated S100A16 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher S100A16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated S100A16 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where S100A16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.612	0.859	.004	20	view →
LUAD	DFS	Median	II,III,IV	0.347	0.668	.032	4	view →
HNSC	OS	Tertile	III,IV	0.917	0.800	.040	2	view →
LSCC	DFS	Median	All	0.973	0.894	.020	1	view →
GBM	DFS	Quartile	All	0.757	0.856	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: S100A16 tumor-vs-normal RNA expression · all S100A16 data types